Hepatocellular Carcinoma

Message from the Guest Editor

As we know, hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and mortality worldwide. It is the fifth most common cause of cancer in men and the seventh in women. The most important causes of HCC are viral hepatitis B and hepatitis C, so their distributions are correlated.

Liver resection, orthotopic liver transplantation, and local treatments are curative options for patients with early and intermediate HCC.

Tyrosine kinase inhibitors are currently considered the standard of care for advanced or intermediate HCC patients’ refractory to locoregional therapy. In recent years, immunotherapy has also been showing promising results in this setting, although recent trials have failed to confirm preliminary results.

Nonetheless, not all patients seem to benefit from these treatments and are thus exposed to unnecessary toxicities without deriving any clinical benefit or survival improvement.

In this scenario, we urgently need clinical and/or biological markers which are able to identify responding patients as well as new treatment options.

mdpi.com/si/34780
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q2 (Oncology)

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI